EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Illumina and Nanopore sequencing in culture-negative samples from suspected lower respiratory tract infection patients

Lichao Ma, Chi Zhu, Tianli Yan, Yun Hu, Juan Zhou, Yajing Li, Furong Du, Jianping Zhou

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1230650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Lichao Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Wuxi Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Wuxi, Jiangsu, Ch…. Hauptthemen laut MEDLINE: Nanopore Sequencing, Respiratory Tract Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the diagnostic value of metagenomic sequencing technology based on Illumina and Nanopore sequencing platforms for patients with suspected lower respiratory tract infection whose pathogen could not be identified by conventional microbiological tests.

Methods

Patients admitted to the Respiratory and Critical Care Medicine in Shanghai Ruijin Hospital were retrospectively studied from August 2021 to March 2022. Alveolar lavage or sputum was retained in patients with clinically suspected lower respiratory tract infection who were negative in conventional tests. Bronchoalveolar lavage fluid (BALF) samples were obtained using bronchoscopy. Sputum samples were collected, while BALF samples were not available due to bronchoscopy contraindications. Samples collected from enrolled patients were simultaneously sent for metagenomic sequencing on both platforms.

Results

Thirty-eight patients with suspected LRTI were enrolled in this study, consisting of 36 parts of alveolar lavage and 2 parts of sputum. According to the infection diagnosis, 31 patients were confirmed to be infected with pathogens, while 7 patients were diagnosed with non-infectious disease. With regard to the diagnosis of infectious diseases, the sensitivity and specificity of Illumina and Nanopore to diagnose infection in patients were 80.6% vs . 93.5% and 42.9 vs . 28.6%, respectively. In patients diagnosed with bacterial, Mycobacterium , and fungal infections, the positive rates of Illumina and Nanopore sequencer were 71.4% vs . 78.6%, 36.4% vs . 90.9%, and 50% vs . 62.5%, respectively. In terms of pathogen diagnosis, the sensitivity and specificity of pathogens detected by Illumina and Nanopore were 55.6% vs . 77.8% and 42.9% vs . 28.6%, respectively. Among the patients treated with antibiotics in the last 2 weeks, 61.1% (11/18) and 77.8% (14/18) cases of pathogens were accurately detected by Illumina and Nanopore, respectively, among which 8 cases were detected jointly. The consistency between Illumina and diagnosis was 63.9% (23/36), while the consistency between Nanopore and diagnosis was 83.3% (30/36). Between Illumina and Nanopore sequencing methods, the consistency ratio was 55% (22/42) based on pathogen diagnosis.

Conclusion

Both platforms play a certain value in infection diagnosis and pathogen diagnosis of CMT-negative suspected LRTI patients, providing a theoretical basis for clinical accurate diagnosis and symptomatic treatment. The Nanopore platform demonstrated potential advantages in the identification of Mycobacterium and could further provide another powerful approach for patients with suspected Mycobacterium infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nanopore SequencingRespiratory Tract InfectionsHumansRetrospective StudiesChinaAnti-Bacterial AgentsBronchoalveolar Lavage FluidMetagenomicsHigh-Throughput Nucleotide SequencingSensitivity and Specificity

Stichwörter der Autor:innen

Illuminabronchoalveolar lavage fluidculture-negative samplelower respiratory tract infectionmetagenomic next-generation sequencingnanopore

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Wuxi Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Wuxi, Jiangsu, China.
  • State Key Laboratory of Neurology and Oncology Drug Development (Jiangsu Simcere Pharmaceutical Co., Ltd, Jiangsu Simcere Diagnostics Co., Ltd.), Jiangsu, China.
  • Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu, China.
  • Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China.

Zitieren

APA

Ma, L., Zhu, C., Yan, T., Hu, Y., Zhou, J., Li, Y., Du, F., & Zhou, J. (2024). Illumina and Nanopore sequencing in culture-negative samples from suspected lower respiratory tract infection patients. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1230650

Vancouver

Ma L, Zhu C, Yan T, Hu Y, Zhou J, Li Y, et al. Illumina and Nanopore sequencing in culture-negative samples from suspected lower respiratory tract infection patients. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1230650

BibTeX
@article{Ma2024,
  author = {Ma, Lichao and Zhu, Chi and Yan, Tianli and Hu, Yun and Zhou, Juan and Li, Yajing and Du, Furong and Zhou, Jianping},
  title = {Illumina and Nanopore sequencing in culture-negative samples from suspected lower respiratory tract infection patients},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1230650}
}
Kostenlos starten →